Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
Clinical trial NCT00960115 · COMPLETED
Trial details
- NCT number
- NCT00960115
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-12-01
- Primary completion
- 2014-05-01
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.